Vor Biopharma INC Form 4 insider transactions

Tirtha Chakraborty, Chief Scientific Officer of Vor Biopharma Inc., disposed of 1,033 shares of common stock on February 6, 2025, to cover tax withholding obligations related to the settlement of restricted stock units.

Robert Ang, CEO of Vor Biopharma, disposed of 2,787 shares of common stock on February 6, 2025, to satisfy tax withholding obligations related to the settlement of restricted stock units.

Eyal C. Attar, Chief Medical Officer of Vor Biopharma, reports the withholding of 1,180 common stock shares to cover tax obligations related to the settlement of restricted stock units on February 6, 2025.

Robert Ang, CEO of Vor Biopharma, reports the repricing of stock options and the grant of restricted stock units (RSUs) in a recent SEC filing.

Tirtha Chakraborty, Chief Scientific Officer of Vor Biopharma, reports a stock option repricing and the acquisition of restricted stock units (RSUs) on February 3, 2025.

Eyal Attar, Chief Medical Officer of Vor Biopharma, reports transactions involving stock options and restricted stock units (RSUs) on February 3, 2025, including a stock option repricing.

Han Wook Choi, CFO of Vor Biopharma, reports the acquisition of stock options and restricted stock units (RSUs) in the company.

Vor Biopharma director Erez Kalir was granted stock options for 60,000 shares at an exercise price of $1.74.

Reprogrammed Interchange LLC and Reid Hoffman have acquired a substantial amount of Vor Biopharma Inc. common stock and warrants, increasing their beneficial ownership.

Eyal C. Attar, Chief Medical Officer of Vor Biopharma Inc., reported selling 10,334 shares of common stock at $1.25 per share on December 27, 2024, according to a Form 4 filing.

RA Capital Management and related entities have acquired a substantial stake in Vor Biopharma, including common stock and warrants, increasing their beneficial ownership.

Chief Scientific Officer Tirtha Chakraborty of Vor Biopharma Inc. sold 875 shares of common stock on November 6, 2024, to cover tax withholding obligations related to the settlement of restricted stock units.

Amy Quinlan, Vice President of Finance at Vor Biopharma Inc., reports the disposition of 206 shares of common stock to cover tax obligations related to restricted stock units.

Eyal C. Attar, Chief Medical Officer of Vor Biopharma Inc., reports a transaction involving the withholding of common stock to cover tax obligations related to the settlement of restricted stock units.

CEO Robert Ang disposed of 2,361 shares of Vor Biopharma Inc. to cover tax obligations related to the settlement of restricted stock units.

Amy Quinlan, Vice President of Finance at Vor Biopharma, reports the withholding of shares to cover tax obligations related to the settlement of restricted stock units.

Tirtha Chakraborty, Chief Scientific Officer of Vor Biopharma Inc., sold 986 shares of common stock on November 1, 2024, to cover tax withholding obligations related to the settlement of restricted stock units.

Eyal C. Attar, Chief Medical Officer of Vor Biopharma Inc., reports the disposal of 1,146 shares of common stock to cover tax obligations related to restricted stock units.

Vor Biopharma CEO Robert Ang disposed of 2,751 shares of common stock on November 1, 2024, to cover tax withholding obligations related to the settlement of restricted stock units.

Han Wook Choi, CFO of Vor Biopharma Inc., reports the acquisition of 400,000 employee stock options on September 30, 2024.

Chief Scientific Officer Tirtha Chakraborty of Vor Biopharma Inc. sold 5,576 shares of common stock on September 3, 2024, to cover tax withholding obligations related to the settlement of restricted stock units.

Vor Biopharma CEO Robert Ang sold 12,657 shares of common stock on September 3, 2024, to cover tax obligations related to the settlement of restricted stock units.

Amy Quinlan, Vice President of Finance at Vor Biopharma Inc., reports the disposal of common stock to cover tax withholding obligations related to the settlement of restricted stock units.

Eyal C. Attar, Chief Medical Officer of Vor Biopharma Inc., reports disposition of shares to cover tax obligations related to restricted stock units.

Robert Ang, CEO of Vor Biopharma Inc., reports disposition of shares to cover tax obligations related to restricted stock units.

Tirtha Chakraborty, Chief Scientific Officer of Vor Biopharma Inc., sold 876 shares of common stock on August 6, 2024, to cover tax withholding obligations related to the settlement of restricted stock units.

Robert Ang, CEO of Vor Biopharma Inc., disposed of 2,751 shares of common stock on August 1, 2024, to satisfy tax withholding obligations related to the settlement of restricted stock units.

Eyal C. Attar, Chief Medical Officer of Vor Biopharma Inc., reports the disposal of 1,146 shares of common stock to cover tax obligations related to the settlement of restricted stock units.

Tirtha Chakraborty, Chief Scientific Officer of Vor Biopharma, sold 985 shares of common stock on August 1, 2024, to cover tax withholding obligations related to the settlement of restricted stock units.

Eyal C. Attar, Chief Medical Officer of Vor Biopharma Inc., sold 14,645 shares of common stock at an average price of $1.39, according to a Form 4 filing with the SEC.